Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureSaul N Faust, Javier Céspedes, Lydiana Avila, Gabriela Ivankovich-Escoto, Helen S Marshall, Peter Richmond, Terry Nolan, Jolanta Bernatoniene, Srini Bandi, Anil Shenoy, Svetlana Rayner, Lisa Weissfeld, Wei Lang, Vivek Samal, Peter Goldstein, Keith Rubin, Camille Locht, Stephanie Noviello
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023
10.1016/s0140-6736(25)01037-2 · 2025
Pertussis before, during, and after Covid-19
10.1038/s44321-025-00199-2 · 2025
Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines
10.3389/fimmu.2019.01344 · 2019
Estimating the duration of pertussis immunity using epidemiological signatures
10.1371/journal.ppat.1000647 · 2009
Live attenuated B pertussis as a single-dose nasal vaccine against whooping cough
10.1371/journal.ppat.0020065 · 2006
Early protection against pertussis induced by live attenuated Bordetella pertussis BPZE1 depends on TLR4
10.4049/jimmunol.1901102 · 2019
Long-term immunity against pertussis induced by a single nasal administration of live attenuated B pertussis BPZE1
10.1016/j.vaccine.2010.08.017 · 2010
A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice
10.1128/cvi.00082-09 · 2009
IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
10.1038/s41385-018-0073-9 · 2018
Live attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection
10.1093/infdis/jix254 · 2017
A phase I clinical study of a live attenuated Bordetella pertussis vaccine—BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers
10.1371/journal.pone.0083449 · 2014
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
10.1016/s1473-3099(20)30274-7 · 2020
Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans
10.1172/jci135020 · 2020
Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults
10.1016/j.vaccine.2022.09.075 · 2022
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial
10.1016/s0140-6736(22)02644-7 · 2023
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
10.1016/j.lanmic.2025.101211 · 2025
Modulation of the infant immune responses by the first pertussis vaccine administrations
10.1016/j.vaccine.2006.06.046 · 2007
Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized
10.1128/iai.68.7.3873-3877.2000 · 2000
Development of high-throughput serum bactericidal assays for Bordetella pertussis to evaluate BPZE1
10.3390/vaccines14060492 · 2026
Correlates of protection induced by vaccination
10.1128/cvi.00131-10 · 2010
BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation
10.1038/s41541-026-01443-7 · 2026
Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells
10.1128/jcm.20.2.167-170.1984 · 1984
Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies
10.1111/j.1574-695x.2005.00001.x · 2006
Immunoglobulin A-mediated protection against Bordetella pertussis infection
10.1128/iai.69.8.4846-4850.2001 · 2001
Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses
10.1038/mi.2016.28 · 2017
Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels
10.4049/jimmunol.0900237 · 2009
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
10.1016/s0264-410x(98)00227-8 · 1998
Global spatial dynamics and vaccine-induced fitness changes of Bordetella pertussis
10.1126/scitranslmed.abn3253 · 2022
Next-generation pertussis vaccines based on the induction of protective T cells in the respiratory tract
10.3390/vaccines8040621 · 2020
IL-17 and IFN-g-producing respiratory tissue-resident memory CD4 T cells persist for decades in adults immunized as children with whole-cell pertussis vaccines
10.1093/infdis/jiae034 · 2024
Complete genome sequences of Bordetella pertussis isolates B1917 and B1920, representing two predominant global lineages
10.1128/genomea.01301-14 · 2014
Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of pertactin-negative strains
10.3389/fmicb.2020.02108 · 2020
No additional external references are available.